Clearmind gets Yale IRB clearance to expand CMND-100 trial recruitment

Clearmind Medicine Inc. announced on September 8, 2026 that Yale University's Institutional Review Board has cleared the company to begin patient recruitment for Parts B and C of its Phase I/II trial of CMND-100.¹

The study is formally titled "A Phase I/II Single and Multiple Dose Tolerability, Safety and Pharmacokinetic Study of CMND-100 in Healthy Volunteers and Subjects with AUD," and the Yale approval lets Clearmind speed up enrollment through the university's Department of Psychiatry.¹

Yale now becomes part of a wider recruitment network for the trial. Other active sites include Johns Hopkins University School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.¹ The Yale arm of the study is headed by Anahita Bassir Nia, MD, who specializes in psychiatry and addiction medicine.¹

The IRB clearance follows previously reported results from Part A of the trial. Clearmind said it had already completed Part A of its FDA-regulated Phase I/II trial with positive safety findings, reporting that all 24 participants across four ascending-dose cohorts finished treatment as planned.¹ The study met its primary endpoint of safety and tolerability, with a consistent safety profile through the highest dose tested in the fourth cohort and no serious adverse events reported.¹

CMND-100 is described by the company as a non-hallucinogenic, MEAI-based compound being studied for Alcohol Use Disorder. Clearmind's patent portfolio currently includes nineteen patent families and 32 granted patents.¹ The company did not disclose a projected completion date for Parts B and C in this release.